Vicore Pharma Holding AB
NASDAQ:VCREMedical - Pharmaceuticals
-$0.24 today
- Market cap
- $279.65M
- Beta
- 0.15
Volume 0.00M
Average 0.26M
VCRE Total Non-current Liabilities
All obligations due after more than one year.
Vicore Pharma Holding ABNASDAQ: VCRE
Total Non-current Liabilities · Q2 FY2026 · quarter ended Jun 2026
Total non-current liabilities of SEK 330.36K in Q2 FY2026
Q2 FY2026 total non-current liabilities was SEK 330.36K.
Context
- Total non-current liabilities amounted to 0.3% of total assets at the end of Q2 FY2026.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Non-current Liabilities history
SEK · from the balance sheet
- Latest · FY2025
- 4.74M SEK
- Year-over-year change
- —
| Period | Period end | Total Non-current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 4.74M | — |
Total Non-current Liabilities vs competitors
How VCRE compares with its peers on the latest reported figures
- Peers report in different currencies, so total non-current liabilities is compared through growth and share of total assets rather than absolute size.
- Total non-current liabilities amounts to 0.3% of total assets for VCRE, versus a peer median of 26.3%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $137.51M USD | -16.1% | +70.1% | 26.3% | |
VCREVicore Pharma Holding AB | Jun 2026 | SEK 330.36K SEK | — | — | 0.3% |
AVLNAvalyn Pharma Inc. Common Stock | — | — | — | — | — |
| Peer median (excluding VCRE) | — | -16.1% | +70.1% | 26.3% | |
Competitors are the stored peer set for VCRE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Vicore Pharma Holding AB
NASDAQ:VCRE
Intrinsic Alpha fair value
Locked
Current Price
$9.90
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.